JP2024515829A5 - - Google Patents
Info
- Publication number
- JP2024515829A5 JP2024515829A5 JP2023566514A JP2023566514A JP2024515829A5 JP 2024515829 A5 JP2024515829 A5 JP 2024515829A5 JP 2023566514 A JP2023566514 A JP 2023566514A JP 2023566514 A JP2023566514 A JP 2023566514A JP 2024515829 A5 JP2024515829 A5 JP 2024515829A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- degrees
- pharmaceutically acceptable
- acceptable salt
- including endpoints
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025074660A JP2025111701A (ja) | 2021-04-29 | 2025-04-28 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181743P | 2021-04-29 | 2021-04-29 | |
| US63/181,743 | 2021-04-29 | ||
| US202163197025P | 2021-06-04 | 2021-06-04 | |
| US63/197,025 | 2021-06-04 | ||
| US202163210810P | 2021-06-15 | 2021-06-15 | |
| US63/210,810 | 2021-06-15 | ||
| US202163239096P | 2021-08-31 | 2021-08-31 | |
| US63/239,096 | 2021-08-31 | ||
| US202163285812P | 2021-12-03 | 2021-12-03 | |
| US63/285,812 | 2021-12-03 | ||
| US202163289506P | 2021-12-14 | 2021-12-14 | |
| US202163289520P | 2021-12-14 | 2021-12-14 | |
| US63/289,506 | 2021-12-14 | ||
| US63/289,520 | 2021-12-14 | ||
| US202263298601P | 2022-01-11 | 2022-01-11 | |
| US63/298,601 | 2022-01-11 | ||
| PCT/US2022/026920 WO2022232504A1 (en) | 2021-04-29 | 2022-04-29 | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025074660A Division JP2025111701A (ja) | 2021-04-29 | 2025-04-28 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515829A JP2024515829A (ja) | 2024-04-10 |
| JP2024515829A5 true JP2024515829A5 (enExample) | 2025-05-09 |
Family
ID=81748925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566514A Pending JP2024515829A (ja) | 2021-04-29 | 2022-04-29 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
| JP2025074660A Pending JP2025111701A (ja) | 2021-04-29 | 2025-04-28 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025074660A Pending JP2025111701A (ja) | 2021-04-29 | 2025-04-28 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240216395A1 (enExample) |
| EP (2) | EP4768044A2 (enExample) |
| JP (2) | JP2024515829A (enExample) |
| KR (1) | KR20240006026A (enExample) |
| AU (1) | AU2022266680A1 (enExample) |
| BR (1) | BR112023022264A2 (enExample) |
| CA (1) | CA3218072A1 (enExample) |
| IL (1) | IL307991A (enExample) |
| MX (1) | MX2023012727A (enExample) |
| TW (1) | TW202308654A (enExample) |
| WO (1) | WO2022232504A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019241442A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| JP2022514510A (ja) * | 2018-12-14 | 2022-02-14 | プラクシス プレシジョン メディスンズ，インコーポレイテッド | うつ病の治療方法 |
| CA3187178A1 (en) | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| JP2025508406A (ja) * | 2022-02-16 | 2025-03-26 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ関連障害を処置するための神経活性ステロイド |
-
2022
- 2022-04-29 MX MX2023012727A patent/MX2023012727A/es unknown
- 2022-04-29 WO PCT/US2022/026920 patent/WO2022232504A1/en not_active Ceased
- 2022-04-29 IL IL307991A patent/IL307991A/en unknown
- 2022-04-29 BR BR112023022264A patent/BR112023022264A2/pt unknown
- 2022-04-29 EP EP26162693.1A patent/EP4768044A2/en active Pending
- 2022-04-29 JP JP2023566514A patent/JP2024515829A/ja active Pending
- 2022-04-29 AU AU2022266680A patent/AU2022266680A1/en active Pending
- 2022-04-29 EP EP22724335.9A patent/EP4329770A1/en not_active Ceased
- 2022-04-29 CA CA3218072A patent/CA3218072A1/en active Pending
- 2022-04-29 US US18/557,691 patent/US20240216395A1/en active Pending
- 2022-04-29 KR KR1020237040558A patent/KR20240006026A/ko active Pending
- 2022-04-29 TW TW111116469A patent/TW202308654A/zh unknown
-
2025
- 2025-04-28 JP JP2025074660A patent/JP2025111701A/ja active Pending